Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 8.7% – Here’s What Happened

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) traded down 8.7% during mid-day trading on Friday . The stock traded as low as $22.90 and last traded at $22.3760. 244,445 shares changed hands during trading, a decline of 82% from the average session volume of 1,366,863 shares. The stock had previously closed at $24.52.

Analysts Set New Price Targets

Several research firms have weighed in on GLUE. Guggenheim increased their price target on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Zacks Research downgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday. JPMorgan Chase & Co. upped their price objective on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Wall Street Zen downgraded Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Finally, Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Monte Rosa Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $33.33.

Monte Rosa Therapeutics Stock Down 7.3%

The stock has a fifty day simple moving average of $19.73 and a 200 day simple moving average of $19.11. The firm has a market capitalization of $1.92 billion, a P/E ratio of -15.36 and a beta of 1.56.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%.The business had revenue of $4.21 million during the quarter, compared to the consensus estimate of $10.95 million. Research analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.23 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Anthony M. Manning sold 10,000 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $23.11, for a total transaction of $231,100.00. Following the completion of the transaction, the director directly owned 10,000 shares of the company’s stock, valued at approximately $231,100. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Sharon Townson sold 6,000 shares of Monte Rosa Therapeutics stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $23.31, for a total value of $139,860.00. Following the completion of the sale, the insider directly owned 67,845 shares in the company, valued at $1,581,466.95. This trade represents a 8.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 81,778 shares of company stock valued at $1,768,581 in the last 90 days. 6.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Hedge funds have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD raised its position in shares of Monte Rosa Therapeutics by 10.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,118,904 shares of the company’s stock valued at $80,265,000 after buying an additional 481,844 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Monte Rosa Therapeutics by 8.6% during the fourth quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock worth $50,905,000 after acquiring an additional 257,547 shares during the period. State Street Corp increased its holdings in Monte Rosa Therapeutics by 148.9% during the 4th quarter. State Street Corp now owns 2,107,480 shares of the company’s stock worth $33,045,000 after purchasing an additional 1,260,707 shares during the period. AQR Capital Management LLC raised its holdings in shares of Monte Rosa Therapeutics by 459.4% in the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock valued at $5,791,000 after acquiring an additional 1,054,406 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Monte Rosa Therapeutics by 4.6% in the 4th quarter. Geode Capital Management LLC now owns 1,204,844 shares of the company’s stock worth $18,896,000 after purchasing an additional 53,278 shares during the period. Hedge funds and other institutional investors own 79.96% of the company’s stock.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.